Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. It has developed monoclonal antibodies to help treat different diseases. Its product areas include vaccines, specialty medicines, and general medicines. Its vaccine portfolio includes more than 20 vaccines that help protect people from a range of diseases and infections throughout their lives. Its specialty medicines include medicines for immune-mediated conditions. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease (COPD), antibiotics, and medicines for skin diseases. It has a global network of about 12 vaccine manufacturing sites.

  • Revenue in GBP (TTM)29.09bn
  • Net income in GBP4.34bn
  • Incorporated1999
  • Employees69.40k
  • Location
    GSK plc980 Great West RoadBRENTFORD TW8 9GSUnited KingdomGBR
  • Phone+44 208 047 5000
  • Fax+44 208 047 7807
  • Websitehttps://www.gsk.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
GSK:LSE since
BELLUS Health IncAnnounced18 Apr 202318 Apr 2023Announced-7.91%1.87bn
Affinivax IncDeal completed31 May 202231 May 2022Deal completed-35.55%3.30bn
Data delayed at least 20 minutes, as of May 26 2023 18:03 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
UCB SA4.79bn364.90m14.04bn8.70k38.521.7416.002.932.162.1528.6947.810.36691.884.82633,919.302.796.233.487.8269.6673.497.6114.760.77029.120.242431.62-4.504.02-60.19-11.0012.162.42
argenx SE491.34m-414.22m18.09bn843.00------36.81-8.64-8.6410.30--------670,855.20---21.60---24.3092.35---84.30-188.60---------17.4058.50-73.81--204.62--
Merck KGaA19.40bn2.82bn18.54bn64.01k22.172.754.210.9567.457.4551.3260.140.47071.885.10347,599.306.865.148.686.7261.8762.6114.5711.920.843628.210.28779.6412.938.908.875.476.6211.97
Genmab A/S1.79bn616.35m21.72bn1.85k35.216.76753.7412.1480.1080.10232.40416.880.5544--5.079,234,940.0019.1019.2720.3120.51----34.4640.71----0.0296--72.0743.9083.5837.9929.07--
HALEON PLC11.22bn1.11bn30.47bn21.00k27.59--71.542.720.11960.11961.21--------534,142.90--------60.83--10.49----8.15----13.76---23.74------
Lonza Group AG5.57bn1.09bn38.11bn17.49k35.004.0123.496.8416.3416.3483.69142.660.36812.285.95355,722.007.205.308.636.4839.1839.9019.5715.201.2721.610.173128.4115.056.4780.2712.8432.934.94
Bayer AG43.87bn2.64bn46.43bn101.74k17.601.315.601.063.093.0951.3941.600.40261.673.46498,071.402.44-1.113.30-1.4559.5458.986.05-3.040.75874.950.5135--15.107.70315.005.024.50-2.72
GSK plc29.09bn4.34bn57.01bn69.40k12.634.828.131.961.103.647.522.890.39231.513.84419,092.206.456.399.8210.4270.4269.5516.4415.900.6949.710.648993.3718.74-0.577851.7310.270.5035-5.53
Sanofi SA40.14bn7.26bn109.02bn91.57k14.95--11.932.726.656.6536.84--------504,504.60--5.80--7.0269.9368.4918.2417.00--102.64--59.8415.864.6234.5217.282.393.28
Novartis AG42.23bn5.69bn181.11bn103.00k30.223.9617.724.292.942.9421.7822.470.43912.036.02464,083.905.929.097.9511.7771.0970.9813.4823.680.793112.260.358659.94-2.153.60-71.05-1.493.093.79
AstraZeneca plc35.52bn3.81bn182.31bn83.50k48.146.2921.685.132.442.4422.7718.710.44521.354.62425,359.104.782.636.313.6280.6378.9910.746.350.69596.820.468187.0718.5314.572,835.716.639.681.13
Roche Holding AG56.61bn11.11bn212.76bn103.61k18.938.3013.693.7615.3615.3678.3235.030.70132.275.65610,743.8015.0016.2125.3125.3370.7571.0721.3822.620.925619.250.441959.330.76433.49-10.837.262.632.74
Novo Nordisk A/S21.97bn7.13bn227.95bn57.09k42.3232.0328.8410.3826.8826.8882.7135.520.84221.294.343,461,659.0027.3429.8355.6758.5884.2283.7632.4732.860.669416.840.242145.8825.689.6416.277.8111.279.57
Data as of May 26 2023. Currency figures normalised to GSK plc's reporting currency: UK Pound GBX

Institutional shareholders

18.71%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 01 May 2023148.76m3.63%
BlackRock Fund Advisorsas of 01 May 2023121.21m2.96%
Dodge & Coxas of 03 Mar 202399.38m2.43%
Schroder Investment Management Ltd.as of 01 May 202369.98m1.71%
Silchester International Investors LLPas of 01 May 202366.61m1.63%
BlackRock Advisors (UK) Ltd.as of 01 May 202364.47m1.57%
Legal & General Investment Management Ltd.as of 01 May 202354.48m1.33%
Mondrian Investment Partners Ltd.as of 01 May 202350.97m1.25%
SSgA Funds Management, Inc.as of 01 May 202348.89m1.19%
Threadneedle Asset Management Ltd.as of 01 May 202341.30m1.01%
More ▼
Data from 31 Mar 2023 - 31 Mar 2023Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.